X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19257) 19257
Publication (1879) 1879
Newsletter (674) 674
Book Review (257) 257
Newspaper Article (39) 39
Book Chapter (37) 37
Magazine Article (25) 25
Dissertation (16) 16
Transcript (16) 16
Conference Proceeding (14) 14
Data Set (6) 6
Trade Publication Article (4) 4
Paper (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15130) 15130
c-reactive protein (14200) 14200
index medicus (10542) 10542
male (10393) 10393
female (10155) 10155
middle aged (8161) 8161
inflammation (6019) 6019
adult (5727) 5727
aged (5590) 5590
c-reactive protein - metabolism (5408) 5408
risk factors (4244) 4244
c-reactive protein - analysis (3255) 3255
biomarkers - blood (3091) 3091
research (2986) 2986
animals (2846) 2846
treatment outcome (2675) 2675
atherosclerosis (2665) 2665
health aspects (2135) 2135
cardiac & cardiovascular systems (2133) 2133
care and treatment (2106) 2106
cardiovascular-disease (2031) 2031
risk (1883) 1883
analysis (1814) 1814
mortality (1800) 1800
cardiovascular disease (1769) 1769
prospective studies (1726) 1726
proteins (1657) 1657
disease (1638) 1638
biomarkers (1630) 1630
coronary-heart-disease (1618) 1618
cytokines (1606) 1606
oxidative stress (1555) 1555
medicine (1549) 1549
cholesterol (1545) 1545
pharmacology & pharmacy (1537) 1537
cardiovascular diseases (1488) 1488
research article (1468) 1468
immunology (1427) 1427
peripheral vascular disease (1406) 1406
double-blind method (1391) 1391
studies (1387) 1387
aged, 80 and over (1354) 1354
diabetes (1348) 1348
endocrinology & metabolism (1337) 1337
physiological aspects (1318) 1318
metabolic syndrome (1280) 1280
interleukin-6 - blood (1274) 1274
obesity (1240) 1240
rheumatology (1236) 1236
patients (1235) 1235
statins (1232) 1232
time factors (1222) 1222
medical research (1199) 1199
adolescent (1194) 1194
drug therapy (1194) 1194
young adult (1193) 1193
prognosis (1192) 1192
myocardial-infarction (1182) 1182
diagnosis (1175) 1175
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1166) 1166
body mass index (1165) 1165
medicine, general & internal (1154) 1154
insulin-resistance (1127) 1127
insulin resistance (1122) 1122
nutrition & dietetics (1121) 1121
inflammation - blood (1085) 1085
hypertension (1083) 1083
rheumatoid arthritis (1017) 1017
follow-up studies (1014) 1014
article (998) 998
medicine, experimental (990) 990
therapy (983) 983
severity of illness index (971) 971
abridged index medicus (962) 962
medicine, research & experimental (958) 958
case-control studies (951) 951
expression (896) 896
lipids (888) 888
mice (884) 884
multidisciplinary sciences (878) 878
interleukin-6 (864) 864
rats (861) 861
association (858) 858
prevention (843) 843
risk-factors (836) 836
dose-response relationship, drug (830) 830
clinical trials (820) 820
coronary-artery-disease (807) 807
hematology (807) 807
retrospective studies (807) 807
blood pressure (794) 794
complications and side effects (794) 794
markers (794) 794
biochemistry & molecular biology (792) 792
science (789) 789
development and progression (780) 780
cross-sectional studies (775) 775
lipids - blood (771) 771
type 2 diabetes (751) 751
inflammation - drug therapy (742) 742
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19502) 19502
Chinese (205) 205
Russian (98) 98
German (62) 62
Spanish (40) 40
French (33) 33
Japanese (26) 26
Polish (19) 19
Hungarian (10) 10
Ukrainian (9) 9
Korean (8) 8
Italian (7) 7
Turkish (7) 7
Portuguese (5) 5
Danish (4) 4
Dutch (4) 4
Swedish (3) 3
Croatian (2) 2
Norwegian (2) 2
Persian (2) 2
Serbian (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Endocrinology, ISSN 0013-7227, 10/2017, Volume 158, Issue 10, pp. 3501 - 3511
Bone morphogenetic protein 2 (BMP2) belongs to the transforming growth factor-beta superfamily and plays a critical role in regulating ovarian follicle... 
OVARY | STEROIDOGENESIS | ACTIVIN-A | FERTILIZATION | BONE MORPHOGENETIC PROTEIN-2 | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | TGF-BETA SUPERFAMILY | PROGESTERONE PRODUCTION | GROWTH-DIFFERENTIATION FACTOR-8 | ESTRADIOL PRODUCTION | Bone Morphogenetic Protein 2 - pharmacology | Luteal Cells - metabolism | Ovulation Induction | Humans | Smad8 Protein - drug effects | Serum Amyloid P-Component - drug effects | Gene Knockdown Techniques | C-Reactive Protein - metabolism | Smad4 Protein - genetics | Smad5 Protein - metabolism | Dioxoles - pharmacology | Female | Benzamides - pharmacology | C-Reactive Protein - drug effects | Phosphorylation - drug effects | Pyrazoles - pharmacology | Luteal Cells - drug effects | Bone Morphogenetic Protein Receptors, Type II - genetics | Enzyme-Linked Immunosorbent Assay | Down-Regulation | Bone Morphogenetic Protein Receptors, Type I - genetics | C-Reactive Protein - genetics | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Activin Receptors, Type I - genetics | Blotting, Western | Serum Amyloid P-Component - genetics | Smad5 Protein - drug effects | Activin Receptors, Type II - genetics | Smad1 Protein - metabolism | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Serum Amyloid P-Component - metabolism | Smad1 Protein - drug effects | Smad8 Protein - metabolism | Phosphorylation | Bone morphogenetic protein 2 | Bone morphogenetic protein receptor type II | Lutein | Homology | Ovulation | Smad4 protein | Signaling | Receptors | Molecular modelling | Luteinizing hormone | Activin | Growth factors | Expansion | Pentraxins
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9670, pp. 1175 - 1182
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | INFLAMMATION | CARDIOVASCULAR-DISEASE | MARKERS | RISK | ACUTE CORONARY SYNDROMES | PRAVASTATIN | PRIMARY PREVENTION | PREDICTION | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 1, pp. 29 - 38
Statins have pleiotropic effects, reducing not only low-density lipoprotein cholesterol levels, but also the levels of C-reactive protein (CRP), an... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | EVENTS | CARDIOVASCULAR-DISEASE | PREVENTION | ATHEROSCLEROSIS | INTRAVASCULAR ULTRASOUND | RANDOMIZED CONTROLLED-TRIAL | SIMVASTATIN | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Secondary Prevention | Coronary Artery Disease - blood | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Lipids - blood | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Risk Factors | Cholesterol, LDL - drug effects | Biomarkers - blood | Coronary Artery Disease - drug therapy | Disease Progression | Atorvastatin Calcium | Regression Analysis | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | C-reactive protein | Research | Coronary heart disease | Patient outcomes | Risk factors | Statins | Ultrasonic imaging | Medical imaging | Atherosclerosis | Cardiovascular disease | Statistical methods | Cholesterol
Journal Article
Osteoarthritis and Cartilage, ISSN 1063-4584, 12/2017, Volume 25, Issue 12, pp. 1952 - 1961
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABT-981, a human dual variable domain immunoglobulin simultaneously... 
ABT-981 | Interleukin-1 | Safety | Osteoarthritis | Pharmacokinetic | Clinical study | RHEUMATOID-ARTHRITIS | CYTOKINES | INTERLEUKIN-1 RECEPTOR ANTAGONIST | RECOMBINANT INTERLEUKIN-1 | RHEUMATOLOGY | III COLLAGENS | CARTILAGE | COLLAGENASE PRODUCTION | DOUBLE-BLIND | ORTHOPEDICS | EXPRESSION | Interleukin-1beta - drug effects | Neutrophils - cytology | Vimentin - drug effects | Collagen Type II - drug effects | Vimentin - metabolism | Humans | Middle Aged | Collagen Type III - metabolism | Male | Vascular Endothelial Growth Factor A - metabolism | Collagen Type II - metabolism | C-Reactive Protein - metabolism | Peptides - metabolism | Injections, Subcutaneous | Female | C-Reactive Protein - drug effects | Leukocyte Count | Vascular Endothelial Growth Factor A - drug effects | Aggrecans - drug effects | Interleukin-1beta - antagonists & inhibitors | Citrullination | Severity of Illness Index | Immunoglobulins - pharmacology | Cartilage Oligomeric Matrix Protein - drug effects | Collagen Type I - metabolism | Injection Site Reaction | Interleukin-1alpha - antagonists & inhibitors | Aggrecans - metabolism | Collagen Type III - drug effects | Peptides - drug effects | Cartilage Oligomeric Matrix Protein - metabolism | Collagen Type I - drug effects | Aged | Erythema | Immunoglobulins - therapeutic use | Osteoarthritis, Knee - drug therapy | Osteoarthritis, Knee - metabolism
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 371, Issue 9617, pp. 998 - 1006
Journal Article